CKD After 225Ac-PSMA617 Therapy in Patients With Metastatic Prostate Cancer
Karyne Pelletier, Gabrielle Côté, Nazanin Fallah‐Rad, Rohan John, Abhijat Kitchlu
Abstract
Targeted radionuclide therapies (TRNT) are novel cancer treatments that deliver radiation selectively to cancer cells and the immediate tumor microenvironment. These agents consist of radiation-emitting radionuclides conjugated with monoclonal antibodies, peptides, or small molecules, each of which are able to specifically target tumor-associated antigens and hence allow for delivery of radiation directly, and almost exclusively, to tumor cells. The radiation emitted by these radionuclide particles causes DNA damage, triggering cancer cell death.
Topics & Concepts
MedicineProstate cancerMonoclonal antibodyCancerRadiation therapyCancer researchCancer cellAntigenRadionuclideAntibodyOncologyInternal medicineImmunologyPhysicsQuantum mechanicsRadiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and ResearchMedical Imaging Techniques and Applications